Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

UNH

Critical Report on UnitedHealth – A Must-Read for Investors

Large-cap Health Care company UnitedHealth has logged a -0.8% change today on a trading volume of 6,694,912. The average volume for the stock is 15,956,426.

UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. Based in Eden Prairie, United States the company has 400,000 full time employees and a market cap of $332,323,323,904. UnitedHealth currently offers its equity investors a dividend that yields 2.3% per year.

The company is now trading 2.78% away from its average analyst target price of $357.0 per share. The 24 analysts following the stock have set target prices ranging from $198.0 to $626.0, and on average give UnitedHealth a rating of buy.

Over the last 12 months UNH shares have declined by -38.1%, which represents a difference of -55.0% when compared to the S&P 500. The stock's 52 week high is $630.73 per share and its 52 week low is $234.6. With its net margins declining an average -8.2% over the last 6 years, UnitedHealth declining profitability gives us reason to believe its stock price will continue to underwhelm.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2024 400,278,000 14,405,000 4 -33.33
2023 371,622,000 22,381,000 6 0.0
2022 324,162,000 20,120,000 6 0.0
2021 287,597,000 17,285,000 6 0.0
2020 257,141,000 15,403,000 6 0.0
2019 242,155,000 13,839,000 6
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS